Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Transitional cell carcinoma (TCC) is a common malignancy.
• NY-ESO-1 is a tumor antigen implicated in various cancers.
• Understanding NY-ESO-1 expression in TCC is crucial for potential therapeutic strategies.

Purpose of the Study:

• To investigate NY-ESO-1 mRNA and protein expression in transitional cell carcinoma.
• To assess the correlation between NY-ESO-1 expression and tumor grade.
• To evaluate the presence of NY-ESO-1 antibodies in TCC patient sera.

Main Methods:

• Reverse transcription-PCR (RT-PCR) was used to detect NY-ESO-1 mRNA.
• Immunohistochemistry with NY-ESO-1-specific monoclonal antibody ES121 was performed.
• Serological assays were conducted to detect NY-ESO-1 antibodies in patient serum.

Main Results:

• NY-ESO-1 mRNA was detected in 32% of TCC specimens, with higher prevalence in high-grade tumors (44% in G3 vs. 0% in G1).
• NY-ESO-1 protein expression was confirmed in 2 of 14 high-grade tumors, but not in lower-grade tumors.
• NY-ESO-1 antibodies were found in 12.5% of patients with high-grade TCC but were absent in low-grade cases.

Conclusions:

• NY-ESO-1 expression is associated with advanced grade and stage in transitional cell carcinoma.
• NY-ESO-1 represents a potential biomarker for high-grade TCC.
• Further research into NY-ESO-1 as a therapeutic target in TCC is warranted.